Please login to the form below

Not currently logged in
Email:
Password:

Dr Véronique Walsh joins BMS UK

Bristol-Myers Squibb UK has appointed Dr Véronique Walsh to the role of business unit director, neuroscience and immunoscience
Bristol-Myers Squibb (BMS) UK has appointed Dr Véronique Walsh to the role of business unit director, neuroscience and immunoscience. She will report to vice president and general manager of BMS UK, Amadou Diarra.

Dr Véronique Walsh, Bristol-Myers Squibb UK
Dr Véronique Walsh


Dr Walsh will lead the sales and marketing teams for BMS' neuroscience and immunoscience portfolio which includes Orencia (abatacept), Abilify (aripiprazole) and Perfalgan (paracetamol IV), as well as investigational products.

Most recently serving as deputy managing director at Sanofi Pasteur MSD UK, and in charge of market access, public affairs, communications, and strategic planning, Dr Walsh has 20 years experience in the vaccines industry. Key achievements during her 14 years at Sanofi Pasteur MSD include the launch of several new vaccines and the development and implementation of market access strategies within the company. 


Before joining the pharmaceutical industry in 1990, Dr Walsh held different hospital and primary care positions in France. She has an MBA from the Business School in Lyon, France, and has completed the Runge Balliol leadership in management course at Oxford. In 2010, she also gained a post graduate certificate in health economics for health professionals from the University of York. 

5th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics